Table 4 Treatment-related adverse events occurring in all subjects
Adverse event | Period 1 (n = 12) | Period 2 (n = 12) |
|---|---|---|
Patients with ≥1 treatment-related adverse event, n (%) | 12 (100) | 12 (100) |
Blood and lymphatic system disorders | ||
Lymphadenopathy | 6 (50) | 7 (58.3) |
General disorders and administration site conditions | ||
Injection site discomfort | 0 (0.0) | 1 (8.3) |
Injection site pain | 3 (25.0) | 5 (41.7) |
Edema peripheral | 12 (100) | 12 (100) |
Injury, poisoning and procedural complications | ||
Contusion | 12 (100) | 12 (100) |
Skin laceration | 2 (16.7) | 2 (16.7) |
Musculoskeletal and connective tissue disorders | ||
Pain in extremity | 11 (91.7) | 11 (91.7) |
Nervous system disorders | ||
Paresthesia | 1 (8.3) | 0 (0.0) |
Skin and subcutaneous tissue disorders | ||
Blood blister | 0 (0.0) | 2 (16.7) |
Pruritus | 5 (41.7) | 10 (83.3) |
Skin discoloration | 0 (0.0) | 1 (8.3) |